Xu Shuai, Avorn Jerry, Kesselheim Aaron S
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):743-9. doi: 10.1161/CIRCOUTCOMES.112.967398. Epub 2012 Oct 23.
Innovative medical devices make major contributions to patient welfare, and coronary stents have been among the most important device developments of recent decades. However, the origins of such breakthrough medical technologies remain poorly understood.
Using a comprehensive database of patents, we identified all individuals and institutions that developed intellectual property related to stent technology early in its development process. The patents were categorized and described using a predetermined qualitative coding strategy. We found 245 granted patents related to bare metal coronary artery stents from 1984 (when the first patent issued in this field) to 1994 (after the first stents were approved). Each year showed an increase in the number of patent filings: from 1 in 1984 to 97 in 1994. The largest fraction of patents was issued to private entities (44.9% of the total). Public companies, individual inventors, and nonprofit institutions represented 31.4%, 18.0%, and 5.7%, respectively. The top 10 most-cited patents in the field were dominated by 2 private entities, Expandable Grafts Partnership and Cook Inc, organizations created by or dependent on the work of independent academic physician-inventors.
Coronary artery stent technology first arose from individual physician-inventors within academic medical centers and their associated private companies. After these initial innovations were in place, the field became dominated by large public companies. This history suggests that policies aimed at encouraging transformative medical device development would have their greatest effect if focused on individual inventors and scientists performing the early stages of technology development.
创新医疗设备对患者福祉做出了重大贡献,冠状动脉支架是近几十年来最重要的设备发展成果之一。然而,此类突破性医疗技术的起源仍鲜为人知。
利用一个全面的专利数据库,我们识别出了在支架技术发展早期开发与其相关知识产权的所有个人和机构。使用预先确定的定性编码策略对专利进行分类和描述。我们发现了1984年(该领域第一项专利发布时)至1994年(第一批支架获批后)期间与裸金属冠状动脉支架相关的245项授权专利。每年的专利申请数量都在增加:从1984年的1项增至1994年的97项。最大比例的专利授予了私人实体(占总数的44.9%)。上市公司、个人发明者和非营利机构分别占31.4%、18.0%和5.7%。该领域被引用次数最多的前10项专利中,有2家私人实体占据主导地位,即可扩张移植物合作组织和库克公司,这两家组织由独立的学术医生发明者创立或依赖其工作。
冠状动脉支架技术最初源自学术医疗中心内的个体医生发明者及其相关的私人公司。在这些最初的创新出现之后,该领域被大型上市公司主导。这段历史表明,旨在鼓励变革性医疗设备开发的政策若聚焦于处于技术开发早期阶段的个体发明者和科学家,将产生最大效果。